Gemma L. Kelly

8.1k total citations · 2 hit papers
59 papers, 4.2k citations indexed

About

Gemma L. Kelly is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Gemma L. Kelly has authored 59 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 35 papers in Molecular Biology and 17 papers in Pathology and Forensic Medicine. Recurrent topics in Gemma L. Kelly's work include Viral-associated cancers and disorders (19 papers), Cancer-related Molecular Pathways (18 papers) and Lymphoma Diagnosis and Treatment (17 papers). Gemma L. Kelly is often cited by papers focused on Viral-associated cancers and disorders (19 papers), Cancer-related Molecular Pathways (18 papers) and Lymphoma Diagnosis and Treatment (17 papers). Gemma L. Kelly collaborates with scholars based in Australia, United Kingdom and United States. Gemma L. Kelly's co-authors include Andreas Strasser, Brandon J. Aubrey, Marco J. Herold, Ana Janic, Alan B. Rickinson, Andrew Bell, Sarah T. Diepstraten, Guillaume Lessène, Deeksha Kaloni and Martin Rowe and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Genes & Development.

In The Last Decade

Gemma L. Kelly

56 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression?

2017 1.0k citations Brandon J. Aubrey, Gemma L. Kelly et al. Cell Death and Differentiation profile →
BCL-2 protein family: attractive targets for cancer therapy

2022 255 citations Deeksha Kaloni, Sarah T. Diepstraten et al. APOPTOSIS profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gemma L. Kelly Australia	30	2.3k	1.9k	837	700	635	59	4.2k
Sara Huerta‐Yépez Mexico	37	2.0k 0.9×	811 0.4×	585 0.7×	736 1.1×	791 1.2×	153	3.9k
Maciej Kujawski United States	28	2.3k 1.0×	2.4k 1.3×	567 0.7×	2.2k 3.1×	850 1.3×	60	5.1k
Seong‐Jin Kim South Korea	44	3.1k 1.4×	1.5k 0.8×	466 0.6×	1.1k 1.6×	824 1.3×	113	4.8k
Adly Yacoub United States	46	3.5k 1.5×	2.0k 1.1×	434 0.5×	678 1.0×	671 1.1×	93	5.6k
Andrei L. Gartel United States	39	5.4k 2.4×	2.3k 1.2×	695 0.8×	440 0.6×	1.2k 1.8×	84	6.8k
Guang Peng United States	33	3.4k 1.5×	1.7k 0.9×	488 0.6×	519 0.7×	823 1.3×	79	4.5k
Priscilla N. Kelly Australia	19	2.5k 1.1×	1.3k 0.7×	308 0.4×	746 1.1×	534 0.8×	92	4.4k
Katsutoshi Oda Japan	35	2.6k 1.1×	1.6k 0.8×	392 0.5×	703 1.0×	786 1.2×	195	4.9k
Keith Harshman Switzerland	26	3.2k 1.4×	1.9k 1.0×	375 0.4×	407 0.6×	906 1.4×	43	5.0k
Min H. Kang United States	38	3.6k 1.6×	1.7k 0.9×	443 0.5×	400 0.6×	689 1.1×	140	5.2k

Countries citing papers authored by Gemma L. Kelly

Since Specialization

Citations

This map shows the geographic impact of Gemma L. Kelly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gemma L. Kelly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gemma L. Kelly more than expected).

Fields of papers citing papers by Gemma L. Kelly

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gemma L. Kelly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gemma L. Kelly. The network helps show where Gemma L. Kelly may publish in the future.

Co-authorship network of co-authors of Gemma L. Kelly

This figure shows the co-authorship network connecting the top 25 collaborators of Gemma L. Kelly. A scholar is included among the top collaborators of Gemma L. Kelly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gemma L. Kelly. Gemma L. Kelly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Thai, Alesha, Richard J. Young, Mathias Bressel, et al.. (2024). Characterizing and Targeting of BCL‐2 Family Members in Nasopharyngeal Carcinoma. Head & Neck. 47(3). 867–877.

Alcolea, Maria P., Direna Alonso‐Curbelo, Chiara Ambrogio, et al.. (2024). Cancer Hallmarks: Piecing the Puzzle Together. Cancer Discovery. 14(4). 674–682. 7 indexed citations

Chen, Tianwei, et al.. (2024). Breathing new insights into the role of mutant p53 in lung cancer. Oncogene. 44(3). 115–129. 14 indexed citations

Diepstraten, Sarah T., et al.. (2023). Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugs. Cell Death and Differentiation. 30(4). 1005–1017. 14 indexed citations

Aubrey, Brandon J., Catherine Chang, Zilu Wang, et al.. (2023). Genome-wide CRISPR screening identifies a role for ARRDC3 in TRP53-mediated responses. Cell Death and Differentiation. 31(2). 150–158. 5 indexed citations

Kaloni, Deeksha, Sarah T. Diepstraten, Andreas Strasser, & Gemma L. Kelly. (2022). BCL-2 protein family: attractive targets for cancer therapy. APOPTOSIS. 28(1-2). 20–38. 255 indexed citations breakdown →

Lieschke, Elizabeth, Zilu Wang, Catherine Chang, et al.. (2022). Flow cytometric single cell-based assay to simultaneously detect cell death, cell cycling, DNA content and cell senescence. Cell Death and Differentiation. 29(5). 1004–1012. 10 indexed citations

Diepstraten, Sarah T., Mary Ann Anderson, Peter E. Czabotar, et al.. (2021). The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs. Nature reviews. Cancer. 22(1). 45–64. 220 indexed citations

Peddigari, Suresh, Carol A. Mercer, Virginia Amador, et al.. (2021). Impaired ribosome biogenesis checkpoint activation induces p53-dependent MCL-1 degradation and MYC-driven lymphoma death. Blood. 137(24). 3351–3364. 17 indexed citations

10.

Brinkmann, Kerstin, Paul Waring, Stefan Glaser, et al.. (2020). BCL‐XL exerts a protective role against anemia caused by radiation‐induced kidney damage. The EMBO Journal. 39(24). e105561–e105561. 6 indexed citations

11.

Teh, Charis E., Alissa K. Robbins, Darren C. Henstridge, et al.. (2020). MCL-1 is essential for survival but dispensable for metabolic fitness of FOXP3+ regulatory T cells. Cell Death and Differentiation. 27(12). 3374–3385. 2 indexed citations

12.

Brennan, Margs S., Catherine Chang, Lin Tai, et al.. (2018). Humanized Mcl-1 mice enable accurate preclinical evaluation of MCL-1 inhibitors destined for clinical use. Blood. 132(15). 1573–1583. 66 indexed citations

13.

Mérino, Delphine, Gemma L. Kelly, Guillaume Lessène, et al.. (2018). BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines. Cancer Cell. 34(6). 879–891. 231 indexed citations

14.

Aubrey, Brandon J., Ana Janic, Yunshun Chen, et al.. (2018). Mutant TRP53 exerts a target gene-selective dominant-negative effect to drive tumor development. Genes & Development. 32(21-22). 1420–1429. 35 indexed citations

15.

Fitzsimmons, Leah & Gemma L. Kelly. (2017). EBV and Apoptosis: The Viral Master Regulator of Cell Fate?. Viruses. 9(11). 339–339. 58 indexed citations

16.

Fitzsimmons, Leah, Wenbin Wei, Catherine Chang, et al.. (2017). Coordinated repression of BIM and PUMA by Epstein–Barr virus latent genes maintains the survival of Burkitt lymphoma cells. Cell Death and Differentiation. 25(2). 241–254. 18 indexed citations

17.

Aubrey, Brandon J., Gemma L. Kelly, Andrew J. Kueh, et al.. (2015). An Inducible Lentiviral Guide RNA Platform Enables the Identification of Tumor-Essential Genes and Tumor-Promoting Mutations In Vivo. Cell Reports. 10(8). 1422–1432. 272 indexed citations

18.

Aubrey, Brandon J., Andreas Strasser, Gemma L. Kelly, Lin Tai, & Marco J. Herold. (2014). Evidence for Mutant p53 Gain-of-Function Effects in Normal Haemopoietic Cells and Myc-Driven Lymphoma. Blood. 124(21). 3589–3589.

19.

Kelly, Gemma L. & Andreas Strasser. (2011). The Essential Role of Evasion from Cell Death in Cancer. Advances in cancer research. 111. 39–96. 76 indexed citations

20.

Kelly, Gemma L., et al.. (2001). Genetic analysis of the Epstein–Barr virus-coded leader protein EBNA-LP as a co-activator of EBNA2 function. Journal of General Virology. 82(12). 3067–3079. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact